CN111778312B - Kit for determining glycylproline dipeptidyl aminopeptidase in serum - Google Patents
Kit for determining glycylproline dipeptidyl aminopeptidase in serum Download PDFInfo
- Publication number
- CN111778312B CN111778312B CN202010542048.0A CN202010542048A CN111778312B CN 111778312 B CN111778312 B CN 111778312B CN 202010542048 A CN202010542048 A CN 202010542048A CN 111778312 B CN111778312 B CN 111778312B
- Authority
- CN
- China
- Prior art keywords
- reagent
- buffer solution
- concentration
- preservative
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
A kit for determining glycylproline dipeptidyl aminopeptidase in serum belongs to the technical field of kits. The kit of the invention comprises an R1 reagent and an R2 reagent; the R1 reagent is a buffer solution containing a protective agent and a preservative; the buffer solution is 3- [ (1, 1-dimethyl-2-hydroxyethyl) amino ] -2-hydroxy propane sulfonic acid buffer solution, triethanolamine buffer solution or trihydroxy aminomethane-hydrochloric acid buffer solution; the protective agent is diglycolamine; the preservative is Proclin300; the R2 reagent is a buffer solution containing a surfactant, a preservative and a substrate; the buffer solution is tartaric acid buffer solution; the surfactant is one or two of polyoxyethylene ether and fatty alcohol polyoxyethylene ether of alkylphenol; the preservative is Proclin300; the substrate is glycyl prolyl paranitroaniline. The kit has high reagent unsealing stability and high-temperature stability and good repeatability; the false result of clinical test is avoided, and the detection efficiency and accuracy are high.
Description
Technical Field
The invention belongs to the technical field of kits, and particularly relates to a kit for determining glycylproline dipeptidyl aminopeptidase in serum.
Background
Hopsu-Havu and Glnner were first discovered and isolated in 1966 from commercial enzyme preparation Acylase I to obtain glycylproline dipeptidylaminopeptidase (GPDA), and then it was confirmed that GPDA exists in tissues such as rat liver, rat kidney, pig kidney, human and various animal serum, human salivary glands and saliva, bovine and human dental pulp and gum.
GPDA is mainly present in tissues such as salivary glands and submaxillary glands of the human body, and saliva and blood contain this enzyme. The main role of GPDA is to hydrolyze the peptide chain between glycylproline and other amino acids located at the N-terminus of the peptide chain. The enzyme activity in serum of patients with liver disease is increased, while that of patients with gastric cancer is decreased. The GPDA activity in serum of primary liver cancer (PHC) and secondary liver cancer patients is obviously higher than that of chronic hepatitis, liver cirrhosis, cholelithiasis, obstructive jaundice and normal control group. Acute hepatitis, chronic liver, liver cirrhosis, obstructive jaundice, etc., and serum GPDA can be raised to different degrees, and the rise amplitude is inferior to that of liver cancer patients. However, serum GPDA is higher than that of patients with liver cancer in severe hepatitis and alcoholic hepatitis. The serum GPDA of gastric cancer patients is obviously reduced, generally about 1/2 of that of normal people. Other benign gastrointestinal lesions. GPDA may also be slightly reduced. The gastric ulcer with larger decrease in size is followed by chronic gastritis and duodenal bulbar ulcer. After gastric cancer is resected, the serum GPDA of the patient has an upward trend.
In the prior art, the substrate required for determining glycyl proline dipeptidyl aminopeptidase is glycyl prolyl paranitroaniline p-toluenesulfonate, and glycyl prolyl paranitroaniline p-toluenesulfonate is very unstable after being directly prepared into an aqueous solution, and is usually used in the daytime, so that inconvenience is caused for clinical biochemical tests, waste is caused, and cost is increased. Therefore, it is important to improve the stability of the reagent.
Tartaric acid (targetable), a carboxylic acid, is present in a variety of plants, such as grape and tamarind, and is also one of the major organic acids in wine. As an antioxidant added to foods, it is possible to impart sour taste to foods. This use is similar to citric acid. Tartaric acid and tannin are used together, can be used as mordant of acid dye, and also can be used for certain developing and fixing operations in photographic industry, and its ferric salt has photosensitivity, so that it can be used for making blueprints. Tartaric acid can be complexed with a variety of metal ions and can be used as a cleaning agent and polishing agent for metal surfaces. In the mirror making industry, tartaric acid is an important auxiliary agent and a reducing agent, and can control the forming speed of silver mirrors to obtain a very uniform coating. However, in the prior art, tartaric acid is not applied to the field of reagents and the application of improving the stability of the reagents is not performed.
Disclosure of Invention
The invention aims to solve the technical problem that reagents used in a detection method of glycyl-proline dipeptidyl aminopeptidase in the prior art are unstable, and provides a kit for detecting glycyl-proline dipeptidyl aminopeptidase in serum.
The invention provides a kit for determining glycylproline dipeptidyl aminopeptidase in serum,
comprising an R1 reagent and an R2 reagent;
the R1 reagent is a buffer solution containing a protective agent and a preservative; the buffer solution is 3- [ (1, 1-dimethyl-2-hydroxyethyl) amino ] -2-hydroxy propane sulfonic Acid (AMPSO) buffer solution with the concentration range of 50-100mM, triethanolamine buffer solution with the concentration range of 8-10g/L or Tris-hydroxy amino methane-hydrochloric acid (Tris-HCl) buffer solution with the concentration range of 60-100 mM; the protective agent is diglycolide, and the concentration of the protective agent in the R1 reagent is 5-50mM; the preservative is Proclin300, and the concentration of the preservative in the R1 reagent is 0.05 to 0.25 weight percent;
the R2 reagent is a buffer solution containing a surfactant, a preservative and a substrate; the buffer solution is tartaric acid buffer solution with the concentration range of 20-100 mM; the surfactant is one or two of polyoxyethylene ether and fatty alcohol polyoxyethylene ether of alkylphenol, and the concentration of the surfactant in the R2 reagent is 0.1-3 wt%; the preservative is Proclin300, and the concentration of the preservative in the R2 reagent is 0.05 to 0.25 weight percent; the substrate is glycyl prolyl p-nitrobenzene, and the concentration of the substrate in the R2 reagent is 6mM.
Preferably, in the R1 reagent, the buffer is 3- [ (1, 1-dimethyl-2-hydroxyethyl) amino ] -2-hydroxypropanesulfonic acid buffer with a concentration of 80 mM.
Preferably, the concentration of the protecting agent in the R1 reagent is 20mM.
Preferably, the concentration of the preservative in the R1 reagent is 0.1wt%.
Preferably, in the R2 reagent, the concentration of the tartaric acid buffer is 50mM.
Preferably, in the R2 reagent, the surfactant is polyoxyethylene lauryl ether, and the concentration is 2wt%.
Preferably, the concentration of the preservative in the R2 reagent is 0.1wt%.
Compared with the prior art, the invention has the beneficial effects that:
according to the kit for determining the glycylproline dipeptidyl aminopeptidase in the serum, tartaric acid is used, so that the unsealing stability and the high-temperature stability of the reagent are improved, and the detection repeatability is good; the false result of clinical test is effectively avoided, the detection efficiency and accuracy are greatly improved, the method is suitable for various full-automatic biochemical analyzers, has wider universality and is convenient to popularize.
The kit for determining the glycylproline dipeptidyl aminopeptidase in the serum has low raw material cost, can replace imported reagents, and saves the expense of patients.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings that are needed in the specific embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and other drawings may be obtained according to these drawings without inventive effort to a person of ordinary skill in the art.
FIG. 1 is a calibration curve of the kit for determining glycylproline dipeptidyl aminopeptidase in serum provided in example 1 of the present invention.
FIG. 2 shows the method of using the kit for producing glycylproline dipeptidyl aminopeptidase in serum.
Detailed Description
For a further understanding of the present invention, preferred embodiments of the invention are described below in conjunction with the detailed description, but it is to be understood that these descriptions are merely intended to illustrate further features and advantages of the invention and are not limiting of the patent claims of the invention.
The kit for determining glycylproline dipeptidyl aminopeptidase in serum comprises an R1 reagent and an R2 reagent.
Wherein the R1 reagent is a buffer solution containing a protective agent and a preservative; the buffer solution is 3- [ (1, 1-dimethyl-2-hydroxyethyl) amino ] -2-hydroxy propane sulfonic acid buffer solution with the concentration range of 50-100mM, triethanolamine buffer solution with the concentration range of 8-10g/L or trihydroxy aminomethane-hydrochloric acid buffer solution with the concentration range of 60-100 mM; the protective agent is diglycolide, and the concentration of the protective agent in the R1 reagent is 5-50mM; the preservative is Proclin300, and the concentration of the preservative in the R1 reagent is 0.05 to 0.25 weight percent;
the R2 reagent is a buffer solution containing a surfactant, a preservative and a substrate; the buffer solution is tartaric acid buffer solution with the concentration range of 20-100 mM; the surfactant is one or two of polyoxyethylene ether and fatty alcohol polyoxyethylene ether of alkylphenol, and the concentration of the surfactant in the R2 reagent is 0.1-3 wt%; the preservative is Proclin300, and the concentration of the preservative in the R2 reagent is 0.05 to 0.25 weight percent; the substrate is glycyl prolyl p-nitrobenzene, and the concentration of the substrate in the R2 reagent is 6mM.
In the above embodiment, the buffer solution in the R1 reagent is preferably a buffer solution of 3- [ (1, 1-dimethyl-2-hydroxyethyl) amino ] -2-hydroxypropanesulfonic acid having a concentration of 80 mM.
In the above embodiment, the concentration of the protecting agent in the R1 reagent is preferably 20mM.
In the above technical scheme, in the R1 reagent, the concentration of the preservative is preferably 0.1wt%.
In the above embodiment, the concentration of the tartaric acid buffer in the R2 reagent is preferably 50mM.
In the technical scheme, in the R2 reagent, the surfactant is preferably polyoxyethylene lauryl ether, and the concentration is preferably 2wt%.
In the above technical scheme, in the R2 reagent, the concentration of the preservative is preferably 0.1wt%.
The detection principle of the kit for determining glycylproline dipeptidyl aminopeptidase in serum is as follows: under alkaline conditions, GPDA catalyzes the hydrolysis of the substrate glycyl prolyl paranitroaniline to form glycyl proline and yellow paranitroaniline, which can cause an increase in absorbance at a specific wavelength, with the rate of absorbance increase being proportional to GPDA activity.
The method of using the kit for assaying glycylproline dipeptidyl aminopeptidase of the present invention in serum is shown in FIG. 2 and Table 1.
TABLE 1
The terms used in the present invention generally have meanings commonly understood by those of ordinary skill in the art unless otherwise indicated.
In order to enable those skilled in the art to better understand the technical solutions of the present invention, the present invention will be described in further detail with reference to examples and drawings.
In the following examples, various processes and methods, which are not described in detail, are conventional methods well known in the art. Materials, reagents, devices, instruments, equipment and the like used in the examples described below are commercially available unless otherwise specified.
Example 1
Glycylproline dipeptidyl aminopeptidase assay kit:
the formula of the R1 reagent is as follows (the solvent is purified water):
| AMP | 50mM |
| bisphaleptide | 20mM |
| Proclin 300 | 0.1wt％ |
| pH | 7.8±0.05(25±0.5℃) |
The formula of the R2 reagent is as follows (the solvent is purified water):
| tartaric acid | 50mM |
| Laurinol polyoxyethylene ether | 1.5wt％ |
| Proclin 300 | 0.1wt％ |
| pH | 4.5±0.05(25±0.5℃) |
| Glycyl prolyl p-nitroaniline | 6mM |
Example 2
Glycylproline dipeptidyl aminopeptidase assay kit:
the formula of the R1 reagent is as follows (the solvent is purified water):
the formula of the R2 reagent is as follows (the solvent is purified water):
| tartaric acid | 80mM |
| Laurinol polyoxyethylene ether | 3.0wt％ |
| Proclin 300 | 0.1wt％ |
| pH | 4.5±0.05(25±0.5℃) |
| Glycyl prolyl p-nitroaniline | 6mM |
Example 3
Glycylproline dipeptidyl aminopeptidase assay kit:
the formula of the R1 reagent is as follows (the solvent is purified water):
| triethanolamine salt | 8g/L |
| Bisphaleptide | 20mM |
| Proclin 300 | 0.1wt％ |
| pH | 7.8±0.05(25±0.5℃) |
The formula of the R2 reagent is as follows (the solvent is purified water):
| tartaric acid | 30mM |
| Laurinol polyoxyethylene ether | 2.0wt％ |
| Proclin 300 | 0.1wt％ |
| pH | 4.5±0.05(25±0.5℃) |
| Glycyl prolyl p-nitroaniline | 6mM |
Example 4
Glycylproline dipeptidyl aminopeptidase assay kit:
the formula of the R1 reagent is as follows (the solvent is purified water):
| Tris-HCl | 60mM |
| bisphaleptide | 5mM |
| Proclin 300 | 0.1wt％ |
| pH | 7.8±0.05(25±0.5℃) |
The formula of the R2 reagent is as follows (the solvent is purified water):
| tartaric acid | 20mM |
| Laurinol polyoxyethylene ether | 0.5wt％ |
| Proclin 300 | 0.1wt％ |
| pH | 4.5±0.05(25±0.5℃) |
| Glycyl prolyl p-nitroaniline | 6mM |
Example 5
Glycylproline dipeptidyl aminopeptidase assay kit:
the formula of the R1 reagent is as follows (the solvent is purified water):
| Tris-HCl | 80 mM |
| bisphaleptide | 5mM |
| Proclin 300 | 0.1wt％ |
| pH | 7.8±0.05(25±0.5℃) |
The formula of the R2 reagent is as follows (the solvent is purified water):
| tartaric acid | 50mM |
| Laurinol polyoxyethylene ether | 0.5wt％ |
| Proclin 300 | 0.1wt％ |
| pH | 4.5±0.05(25±0.5℃) |
| Glycyl prolyl p-nitroaniline | 6mM |
Example 6
Glycylproline dipeptidyl aminopeptidase assay kit:
the formula of the R1 reagent is as follows (the solvent is purified water):
| Tris-HCl | 100mM |
| bisphaleptide | 5mM |
| Proclin 300 | 0.1wt％ |
| pH | 7.8±0.05(25±0.5℃) |
The formula of the R2 reagent is as follows (the solvent is purified water):
| tartaric acid | 100mM |
| Laurinol polyoxyethyleneEthers | 0.5wt％ |
| Proclin 300 | 0.25wt％ |
| pH | 4.5±0.05(25±0.5℃) |
| Glycyl prolyl p-nitroaniline | 6mM |
Example 7
Glycylproline dipeptidyl aminopeptidase assay kit:
the formula of the R1 reagent is as follows (the solvent is purified water):
| Tris-HCl | 80mM |
| bisphaleptide | 20mM |
| Proclin 300 | 0.05wt％ |
| pH | 7.8±0.05(25±0.5℃) |
The formula of the R2 reagent is as follows (the solvent is purified water):
| tartaric acid | 50mM |
| Laurinol polyoxyethylene ether | 0.5wt％ |
| Proclin 300 | 0.05wt％ |
| pH | 4.5±0.05(25±0.5℃) |
| Glycyl prolyl p-nitroaniline | 6mM |
Example 8
Glycylproline dipeptidyl aminopeptidase assay kit:
the formula of the R1 reagent is as follows (the solvent is purified water):
| Tris-HCl | 80mM |
| bisphaleptide | 20mM |
| Proclin 300 | 0.1wt％ |
| pH | 7.8±0.05(25±0.5℃) |
The formula of the R2 reagent is as follows (the solvent is purified water):
example 9
Glycylproline dipeptidyl aminopeptidase assay kit:
the formula of the R1 reagent is as follows (the solvent is purified water):
| AMP | 80mM |
| bisphaleptide | 20mM |
| Proclin 300 | 0.25wt％ |
| pH | 7.8±0.05(25±0.5℃) |
The formula of the R2 reagent is as follows (the solvent is purified water):
| tartaric acid | 50mM |
| Laurinol polyoxyethylene ether | 0.5wt％ |
| Proclin 300 | 0.25wt％ |
| pH | 4.5±0.05(25±0.5℃) |
| Glycyl prolyl p-nitroaniline | 6mM |
Example 10
Glycylproline dipeptidyl aminopeptidase assay kit:
the formula of the R1 reagent is as follows (the solvent is purified water):
| triethanolamine salt | 10g/L |
| Bisphaleptide | 20mM |
| Proclin 300 | 0.1wt％ |
| pH | 7.8±0.05(25±0.5℃) |
The formula of the R2 reagent is as follows (the solvent is purified water):
example 11
Glycylproline dipeptidyl aminopeptidase assay kit:
the formula of the R1 reagent is as follows (the solvent is purified water):
| Tris-HCl | 80mM |
| bisphaleptide | 20mM |
| Proclin 300 | 0.1wt％ |
| pH | 7.8±0.05(25±0.5℃) |
The formula of the R2 reagent is as follows (the solvent is purified water):
| tartaric acid | 50mM |
| Laurinol polyoxyethylene ether | 2wt％ |
| Proclin 300 | 0.1wt％ |
| pH | 4.5±0.05(25±0.5℃) |
| Glycyl prolyl p-nitroaniline | 6mM |
Performance tests were performed on the glycylproline dipeptidyl aminopeptidase assay kits in serum of examples 1-11.
1. Accuracy investigation
The high/low value quality control was tested with the glycylproline dipeptidyl aminopeptidase assay kit of example 1-example 6, respectively, and repeated 3 times, and the average value was taken, and the result average value was compared with the theoretical value of the high/low value quality control, and the relative deviation (%) was calculated, requiring the relative deviation to be less than 10%.
TABLE 1 accuracy test results
As can be seen from the results in Table 1, the results of the glycylproline dipeptidyl aminopeptidase assay kits for serum of examples 1-6 according to the present invention all meet the standard requirements, wherein the relative deviation of example 5 is the smallest and the accuracy test results are the best.
2. Stability investigation
High temperature stability: the R1 reagent and the R2 reagent of example 7-example 9 were placed in a 37℃incubator and a 2-8℃refrigerator, respectively, and the reagents were removed and tested simultaneously on days 7, 14 and 21, respectively. And (3) respectively testing the high/low value quality control, repeating the test for 3 times, taking an average value, comparing the average value of the high temperature test result with the average value of the test result at the temperature of 2-8 ℃, and calculating the relative deviation (%) to be less than 15%.
Note that: after the R1 reagent and the R2 reagent at 37℃are taken out from the incubator, the R1 reagent and the R2 reagent refrigerated at 2-8℃are left to reach the same temperature and then tested.
TABLE 2 high temperature stability test results
On-board stability: after the R1 reagent and the R2 reagent of the example 10 and the example 11 are opened, the reagent is placed in a full-automatic biochemical analyzer to test high/low value quality control products respectively, and the opened R1 reagent and R2 reagent are taken out from 7 th, 14 th, 21 th and 28 th days to be tested simultaneously with the cold-stored R1 reagent and R2 reagent at the temperature of 2-8 ℃. Repeating the test for 3 times, taking an average value, comparing the average value of the high-temperature test result with the average value of the refrigeration test result at the temperature of 2-8 ℃, and calculating the relative deviation (%) which is required to be less than 15%.
Table 3 on-board stability test results
As can be seen from the results of tables 2 and 3, the R1 and R2 reagents of examples 7 to 9 according to the present invention were stable at 37℃for 21 days, and the R1 and R2 reagents of example 8 were most stable at 37℃; the R1 and R2 reagents of examples 10-11 of the present invention were stable for 28 days under unsealed conditions, with example 11 being most stable.
3. Calibration curve
Nine-intensity calibrator was tested using the glycylproline dipeptidyl aminopeptidase assay kit of example 1, and a calibration curve was drawn with calibrator concentration on the abscissa and absorbance values on the ordinate, as shown in fig. 1.
It is apparent that the above examples are given by way of illustration only and are not limiting of the embodiments. Other variations or modifications of the above description will be apparent to persons of ordinary skill in the art. It is not necessary here nor is it exhaustive of all embodiments. And obvious variations or modifications thereof are contemplated as falling within the scope of the present invention.
Claims (7)
1. A kit for determining glycylproline dipeptidyl aminopeptidase in serum is characterized in that,
comprising an R1 reagent and an R2 reagent;
the R1 reagent is a buffer solution containing a protective agent and a preservative; the buffer solution is 3- [ (1, 1-dimethyl-2-hydroxyethyl) amino ] -2-hydroxy propane sulfonic acid buffer solution with the concentration range of 50-100mM, triethanolamine buffer solution with the concentration range of 8-10g/L or trihydroxy aminomethane-hydrochloric acid buffer solution with the concentration range of 60-100 mM; the protective agent is diglycolide, and the concentration of the protective agent in the R1 reagent is 5-50mM; the preservative is Proclin300, and the concentration of the preservative in the R1 reagent is 0.05 to 0.25 weight percent;
the R2 reagent is a buffer solution containing a surfactant, a preservative and a substrate; the buffer solution is tartaric acid buffer solution with the concentration range of 20-100 mM; the surfactant is one or two of polyoxyethylene ether and fatty alcohol polyoxyethylene ether of alkylphenol, and the concentration of the surfactant in the R2 reagent is 0.1-3 wt%; the preservative is Proclin300, and the concentration of the preservative in the R2 reagent is 0.05 to 0.25 weight percent; the substrate is glycyl prolyl p-nitrobenzene, and the concentration of the substrate in the R2 reagent is 6mM.
2. The kit for determining glycylproline dipeptidyl aminopeptidase in serum according to claim 1, wherein the buffer in the R1 reagent is 3- [ (1, 1-dimethyl-2-hydroxyethyl) amino ] -2-hydroxypropanesulfonic acid buffer having a concentration of 80 mM.
3. The kit for determining glycylproline dipeptidyl aminopeptidase in serum according to claim 1, wherein the concentration of the protecting agent in the R1 reagent is 20mM.
4. The kit for determining glycylproline dipeptidyl aminopeptidase in serum according to claim 1, wherein the concentration of the preservative in the R1 reagent is 0.1wt%.
5. The kit for determining glycylproline dipeptidyl aminopeptidase in serum according to claim 1, wherein the concentration of the tartaric acid buffer in the R2 reagent is 50mM.
6. The kit for determining the dipeptidyl proline aminopeptidase in serum according to claim 1, wherein the surfactant in the R2 reagent is polyoxyethylene lauryl ether, and the concentration is 2wt%.
7. The kit for determining glycylproline dipeptidyl aminopeptidase in serum according to claim 1, wherein the concentration of the preservative in the R2 reagent is 0.1wt%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010542048.0A CN111778312B (en) | 2020-06-15 | 2020-06-15 | Kit for determining glycylproline dipeptidyl aminopeptidase in serum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010542048.0A CN111778312B (en) | 2020-06-15 | 2020-06-15 | Kit for determining glycylproline dipeptidyl aminopeptidase in serum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111778312A CN111778312A (en) | 2020-10-16 |
| CN111778312B true CN111778312B (en) | 2023-05-12 |
Family
ID=72756437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010542048.0A Active CN111778312B (en) | 2020-06-15 | 2020-06-15 | Kit for determining glycylproline dipeptidyl aminopeptidase in serum |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111778312B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113075139B (en) * | 2021-03-29 | 2022-10-11 | 迪瑞医疗科技股份有限公司 | Stable double-reagent blood ammonia determination kit |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104880423A (en) * | 2015-05-08 | 2015-09-02 | 浙江蓝森生物科技有限公司 | Method, reagent and kit for quantitatively determining activity of glycylproline dipeptidyl aminopeptidase in human serum |
| CN109580505A (en) * | 2018-11-07 | 2019-04-05 | 北京九强生物技术股份有限公司 | A kind of stabiliser compositions |
| CN111154834A (en) * | 2019-12-15 | 2020-05-15 | 金华市强盛生物科技有限公司 | Leucine aminopeptidase detection kit and preparation method thereof |
-
2020
- 2020-06-15 CN CN202010542048.0A patent/CN111778312B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104880423A (en) * | 2015-05-08 | 2015-09-02 | 浙江蓝森生物科技有限公司 | Method, reagent and kit for quantitatively determining activity of glycylproline dipeptidyl aminopeptidase in human serum |
| CN109580505A (en) * | 2018-11-07 | 2019-04-05 | 北京九强生物技术股份有限公司 | A kind of stabiliser compositions |
| CN111154834A (en) * | 2019-12-15 | 2020-05-15 | 金华市强盛生物科技有限公司 | Leucine aminopeptidase detection kit and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111778312A (en) | 2020-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3168195B2 (en) | Improved immunohistochemical staining method and reagents therefor | |
| CN102899388B (en) | Measure the composition of glycated proteins | |
| CN109239059B (en) | Glycated serum protein assay kit and preparation method and application thereof | |
| JP2002524085A (en) | Chromogenic combinations for quantification of (per) oxidases | |
| Blackwood et al. | An improved test for the quantitative determination of trypsin, trypsin-like enzymes, and enzyme inhibitors | |
| EP0223977B1 (en) | Colour developing method in clinical examinations | |
| CN107870170B (en) | A kind of kit of luminol chemiluminescence analysis measurement glycated albumin | |
| DE3331588A1 (en) | AMID COMPOUNDS | |
| Sasaki et al. | A fluorometric method for the determination of the tryptophan content of proteins | |
| JPS60259185A (en) | Method for obtaining glycerine oxidase | |
| CN111778312B (en) | Kit for determining glycylproline dipeptidyl aminopeptidase in serum | |
| US4493892A (en) | Solvent system for peroxidase inhibitor reagent for fecal occult blood determinations | |
| DE2801070A1 (en) | COLORIMETRIC PROCEDURE FOR THE DETERMINATION OF GAMMA-GLUTAMYL TRANSPEPTIDASE ENZYMACTIVITY | |
| CN107505470A (en) | Stable creatinine detection reagent box and its application method | |
| JP2001057897A (en) | Production of fructosylvaline | |
| JPS62220199A (en) | Method and reagent for measuring total bilirubin in specimenof body fluids | |
| EP0636885B1 (en) | Method for determining the fructosamine content | |
| JP7226955B2 (en) | Measurement of glycated protein | |
| JP3674015B2 (en) | Urea nitrogen measurement method and kit for the measurement | |
| US6379915B1 (en) | Diagnostic compositions and devices utilizing same | |
| CN111500672B (en) | Glycylproline dipeptide aminopeptidase determination kit with high analysis sensitivity and preparation method and application thereof | |
| CN115290584B (en) | Stable unsaturated iron binding force measuring kit | |
| US10989714B2 (en) | Measurement of glycoprotein | |
| EP0240964B1 (en) | Reagent for the enzymatic determination of primary c1-c4 alcohols and related method | |
| JPS5876100A (en) | Use of laccase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |